A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus.

MLA

Burggraaf, Benjamin, et al. “A Placebo-Controlled Proof-of-Concept Study of Alirocumab on Postprandial Lipids and Vascular Elasticity in Insulin-Treated Patients with Type 2 Diabetes Mellitus.” Diabetes, Obesity & Metabolism, vol. 22, no. 5, May 2020, pp. 807–16. EBSCOhost, https://doi.org/10.1111/dom.13960.

APA

Burggraaf, B., Pouw, N. M. C., Arroyo, S. F., van Vark-van der Zee, L. C., van de Geijn, G.-J. M., Birnie, E., Huisbrink, J., van der Zwan, E. M., Mulder, M. T., Rensen, P. C. N., de Herder, W. W., & Cabezas, M. C. (2020). A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism, 22(5), 807–816. https://doi.org/10.1111/dom.13960

Chicago

Burggraaf, Benjamin, Nadine M C Pouw, Salvador Fernández Arroyo, Leonie C van Vark-van der Zee, Gert-Jan M van de Geijn, Erwin Birnie, Jeannine Huisbrink, et al. 2020. “A Placebo-Controlled Proof-of-Concept Study of Alirocumab on Postprandial Lipids and Vascular Elasticity in Insulin-Treated Patients with Type 2 Diabetes Mellitus.” Diabetes, Obesity & Metabolism 22 (5): 807–16. doi:10.1111/dom.13960.